Here are relevant reports on : protein-therapeutics-market
-
Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market – (Pipeline Forecast & Market Forecast in G8 Countries) (2011 – 2020)
The incidence of acute lymphocytic leukemia is high in children from 0 to 14 years than the people aged above 14. It is the most common childhood acute lymphocytic leukemia. However, the acute lymphocytic leukemia may also occur in adults. Acute lymphocytic leukemia distribution depends on age. For instance, 30% of is diagnosed before the age of 5 and 55% of ALL age 15.The acute lymphocytic leukemia market is segmented into two types; namely childhood acute lymphocytic leukemia, and adult acute lymphocytic leukemia. The market was dominated by Hyper-CVAD regimen in 2010. However, in 2020, the market is expected to be equally dominated by Hyper-CVAD and Linker regimen.
- Published: December 2013
- Price: $ 4950
- TOC Available:
-
Chronic Lymphocytic Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Chronic lymphocytic leukemia is the second most common cancer in adult males and rarely occurs in children. The risk of chronic lymphocytic leukemia is closely associated with age. About 90% of chronic lymphocytic leukemia is diagnosed in middle age. Incidence rate of CLL is high in men and women over 50 years of age. The chronic lymphocytic leukemia market is segmented into two types; namely childhood chronic lymphocytic leukemia and adulthood lymphocytic leukemia. The market was dominated by Campath drug in 2010. However, in 2020, the market is expected to be equally dominated by GA101/RG7159 molecule and Arzerra drug.
- Published: December 2011
- Price: $ 4950
- TOC Available:
-
Acute Myeloid Leukemia Therapeutics Market in G8 Countries (2010 - 2020)
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age. Incidence rate of acute myeloid leukemia is high in men and women over 50 years. The acute myeloid leukemia market is segmented into two types; namely childhood acute myeloid leukemia and adulthood acute myeloid leukemia. The market was dominated by AVD regimen in 2010. However, in 2020, the market is expected to be dominated by AVD regimen, Cyatarabine, and Quizartinib drug.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Global Nanomedical Devices and Therapeutics Market (2011-2016)
Nanomedicine, an application of nanotechnology in medical science, is an evolving market. It represents an important segment of nanotechnology which will significantly change the course of treating life threatening diseases. This, unlike other treatment options, is significantly expected to enhance efficacy and minimize overall adversities. Toxicity and environmental impact of nanoscale materials are the major problems nanomedicine. Research and development in nanomedicine is expected to offer a pool of novel products which will improve the health of patients. The robust product pipeline for nanobiomaterials poses a health picture of the market creates significant growth opportunities. However these will have to go through stringent testing protocols before commercialization.
- Published: February 2026
- Price: $ 4950
- TOC Available:
-
Protein Characterization Market / Protein Identification Market by Instruments (Chromatography, Electrophoresis, Mass Spectrometry), Consumables & Services, Application (Clinical Diagnosis, Drug Discovery), End User (Pharma, Biotech, CROs) & Region - Global Forecast to 2026
The global protein characterization market growth is primed to transition from $12.6 billion in 2021 to $23.9 billion by 2026, showcasing a strong CAGR of 13.7%. Growth in the protein identification market can mainly be attributed to factors such as rising acceptance of personalized medicine, technological advancement and increased drug discovery & development activities.
- Published: September 2021
- Price: $ 4950
- TOC Available:
-
Reporter Gene Assay Market by Reagents & Assay kits (Luciferase, Green Fluorescent Protein, â-glucuronidase, â-galactosidase), Application (Gene Regulation, Protein Interaction, Cell Signalling Pathways), End Users, Region - Global Forecast to 2024
The reporter gene assay market is projected to reach USD 2.6 billion by 2024, at a CAGR of 10.1%. Factors contributing to the growth of this market include increasing funding for cell-based research, growing applications of gene expression, and rising preference for cell-based assays. The prominent players in the reporter gene assays market are Thermo Fisher Scientific (US), Bio-Rad Laboratories (US), Merck (Germany), PerkinElmer (US), Promega Corporation (US), Biotium (US), Abcam plc (UK), Danaher Corporation (US), Geno Technology (US), Genecopoeia, Inc. (US), InvivoGen (France), PromoCell (Germany), Becton, Dickinson and Company (US), Biotium, Inc. (US), Canvax (Spain), LI-COR, Inc. (US), System Biosciences, LLC (US), Indigo Biosciences, Inc. (US), BioThema (Sweden), Takara Bio Inc (US), BioAssay Systems (US), Cell Biolabs, Inc. (US), BPS Bioscience, Inc (US), Biosynth AG (Switzerland), and Cayman Chemical (US).
- Published: March 2019
- Price: $ 4950
- TOC Available:
-
Protein Engineering Market by Technology (Rational Design, Irrational Design), Product & Service (Instrument, Consumables), Protein Type (Monoclonal Antibodies, Insulin), End User (Academics Institutes, Biopharmaceuticals, CROs) & Region - Global Forecast to 2024
The global protein engineering market growth is primed to transition from $2.2 billion in 2019 to $3.9 billion by 2024, showcasing a strong CAGR of 12.4%. The growth of this market is majorly driven by factors such as the increasing investments in synthetic biology and the growing focus on protein-based drug development by pharmaceutical and biotechnology companies.
- Published: January 2020
- Price: $ 4950
- TOC Available:
-
Fishery By-products Market by Type (Protein & Protein Derivative, Fish Oil, Bioactives & Specialty Compound), Source (Marine, Aquaculture), End-user Industry (Food & Beverage, Animal Feed, Agriculture), Technology, & Region - Global Forecast to 2030
The fishery by-products market is projected to expand from USD 26.34 billion in 2025 to USD 37.46 billion by 2030, at a CAGR of 7.3% during the forecast period. The report profiles key players such as Pesquera Diamante Peru (Peru), Oceana Group Limited (South Africa), Scoular Company (US), Austevoll Seafood ASA (Norway), Maruha Nichiro Corporation (Japan), Nippon Suisan Kais (Japan), Sopropêche (France), and Thai Union Ingredients (Thailand).
- Published: August 2025
- Price: $ 4950
- TOC Available:
-
Functional Proteins Market by Type (Whey Protein Concentrates, Isolates, Hydrolysates, Casein, Soy Protein), Source (Animal, Plant), Form (Dry, Liquid), Application and Region - Trends and Forecast to 2030
The global functional proteins market was valued at USD 4.6 billion in 2020 to reach USD 6.1 billion by 2025, at a compound annual growth rate (CAGR) of 5.6% during the forecast period. Key players mentioned in the report such as ADM (US), DuPont (US), Cargill (US), Ingredion (US), Arla Foods (UK), Roquette (France), BASF (Germany), Glanbia (Ireland), Fonterra (New Zealand), DSM (Netherlands), FrieslandCampina (Netherlands), Essentia Protein Solutions (UK), Amai Proteins (Israel), Mycorena (Sweden), Merit Functional Foods (Canada), Plantible Foods (US), BENEO (Germany), ProtiFarm (Gelderland), and Omega Protein (US).
- Published: March 2021
- Price: $ 4950
- TOC Available:
-
Cell-free Protein Synthesis Market by Offering (Cell Extract Systems (Prokaryotic, Mammalian, Plant), Kits, Instruments, Services), Workflow, Method (Coupled TX/TL, Transcription, Translation), Application (Protein Purification) - Global Forecast to 2030
The global cell-free protein synthesis market, valued at US$203.9 million in 2024, stood at US$217.2 million in 2025 and is projected to advance at a resilient CAGR of 7.3% from 2024 to 2030, culminating in a forecasted valuation of US$308.9 million by the end of the period. Market growth is driven by increasing demand for biologics, vaccines, and personalized medicine, advancements in CFPS technologies, the need for quick prototyping of complex proteins, and the demand for commercial-scale validation of cell-free protein expression systems.
- Published: October 2025
- Price: $ 4950
- TOC Available:
Records 11 to 20 of 50
